Newcard

What Newcard does

Newcard is a French regulated health-technology company founded in 2016 that operates a remote patient monitoring platform for chronic diseases, with current focus on chronic heart failure (CHF), advanced chronic kidney disease (CKD stage IV/V), renal transplantation, and — as of 2026 — left ventricular assist device (LVAD) recipients. The platform combines CE-marked Bluetooth-connected devices (scale, blood pressure monitor), a 4G-enabled patient tablet with iOS/Android applications, and a physician-facing medical platform (app.newcard.io) where algorithm-generated clinical alerts are pre-filtered by a dedicated human medical plateau (IDE nurses and medical assistants) before escalation to the prescribing cardiologist or nephrologist. As of 2025 the company reports approximately 14,000 patients included, 700 prescribers, 120 hospitals and clinics (CHU/CH/cliniques), and 36 million clinical measurements collected, with documented clinical outcomes including a 74.2% relative reduction in heart-failure hospitalization rate and 61.1% reduction in total healthcare costs in a 147-patient CHU de Reims study.

The business operates a B2B2C subscription model under the French Assurance Maladie droit commun telesurveillance framework (effective 1 July 2023), with regulated per-patient monthly forfaits of €28 (socle), €56 (majoré niveau 1), and €70 (majoré niveau 2) for cardiology, fully reimbursed at 100% for ALD patients. Healthcare professionals cannot charge above the regulated tariffs. A 2025 integration of RESIP's jFSE billing engine enables automated SESAM-Vitale electronic claims transmission directly from the platform, materially reducing administrative friction. Ownership is held as an SAS with Ramsay Santé (20% stake, announced 2022) as a strategic-shareholder channel partner, La Poste Santé (~27% stake, 2020–2021) contributing operational nursing-plateau synergies, and Sparkling Partners as founding ecosystem investor; registered share capital is €3,511. The company is headquartered in Wambrechies (Lille metropolitan area), was incubated at Eurasanté, and is led by Director General Pierre Emmanuel Bonnet with Dr Grégory Perrard serving as Medical Director and co-founder.

Recent strategic activity centers on product surface expansion and internationalization: the Belgium launch in 2025 marked the first non-French market, the LVAD monitoring module plus ePRO/eCRF research tools were launched at JESFC 2026, automated billing was promoted via a January 2026 webinar, and the nephrology service was extended to CKD stage IV/V patients in 2024. Compliance posture is unusually strong for a company of this size — CE Class I marking (Directive 93/42/CEE), ANS interoperability/security certification (v1.2.2), HDS hosting in France via ATE, RGPD compliance, and HAS-aligned clinical protocols — collectively forming a regulatory moat that defines who can and cannot enter the French telesurveillance market.

Name

Newcard

Legal name

NEWCARD, SAS

Website

https://newcard.io

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Newcard is a French health-technology company that provides a CE-marked remote patient monitoring platform — connected devices plus a physician portal — for cardiologists and nephrologists managing chronic heart failure, advanced kidney disease, and LVAD patients, reimbursed via Assurance Maladie monthly forfaits and used by ~700 prescribers across ~120 facilities.

Ownership category

akta.pro rank

Product category

Remote Patient Monitoring

NAICS

All Other Outpatient Care Centers (621498)

SIC

Services-Health Services (8000), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

akta.pro secondary industries

Cardiology Telemedicine Platforms (HLALAGAB), Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN) (HLALADAD)

Keywords

• Remote patient monitoring
• Cardiac telemetry services
• Renal telemedicine services
• Connected medical devices
• Chronic disease management

Headquarters

HQ city

Wambrechies

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Remote Monitoring Operator Forfait (Monthly Subscription per Patient): Healthcare professionals (cardiologists, nephrologists) pay a monthly per-patient fee reimbursed by French Assurance Maladie. For cardiac monitoring, three tiers exist: socle (€28/month), majoré niveau 1 (€56/month), and majoré niveau 2 (€70/month). Nephrology monitoring follows analogous billing codes. The fee covers the full remote monitoring service including device kit, platform access, alert management, and therapeutic support.
2. Integrated Billing Service (jFSE): Newcard integrates SESAM-Vitale billing directly into its platform via RESIP's jFSE engine, enabling teletransmission of feullies de soins électroniques. While the billing service itself is bundled with the platform, it represents a value-added feature that reduces administrative friction for prescribers and supports long-term platform stickiness.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Newcard provides remote medical monitoring (télésurveillance) services for patients suffering from chronic heart failure and chronic kidney disease. Healthcare professionals prescribe these subscriptions to their patients, who are equipped with a connected device kit (Bluetooth scale, blood pressure monitor, 4G tablet) that transmits biometric data to Newcard's clinical algorithm. Algorithm-generated alerts are systematically validated by a qualified human medical team before being escalated to the prescribing physician, and the platform automates Assurance Maladie billing via SESAM-Vitale.

Product overview

Newcard offers a unified humanized telemonitoring platform for chronic pathologies, comprising two core services — '1 Minute pour mon Coeur' (heart failure) and '1 Minute pour mes Reins' (renal disease stage 4/5 and transplants) — supported by a shared medical platform, patient application, and connected device kit. The platform also embeds an integrated SESAM-Vitale billing engine and offers research modules (ePRO, eCRF) plus an LVAD monitoring add-on. The architecture follows a hub-and-spoke model: patient data flows from Bluetooth-connected devices through a tablet application to the medical platform where algorithms generate validated alerts for physician action.

Differentiator

Problem solved

Functional benefit

Brands

• 1 Minute pour mon Coeur: Remote monitoring solution for chronic heart failure patients, collecting daily weight, blood pressure, heart rate, and symptom data via connected devices.
• 1 Minute pour mes Reins

Products and services

• 1 Minute pour mon Coeur Remote medical monitoring service for chronic heart failure patients. Prescribed by cardiologists, the service equips patients with a connected device kit (Bluetooth scale, blood pressure monitor, 4G tablet) and runs their biometric data through Newcard's clinical algorithm with alerts validated by a human medical team before escalation to the prescriber.
• 1 Minute pour mes Reins Remote medical monitoring service for chronic kidney disease patients. Prescribed by nephrologists, the service provides a connected device kit and clinical algorithm-based monitoring with human-validated alerts escalated to the prescribing physician, with automated Assurance Maladie billing.
• Plateforme Médicale Newcard Cloud-based medical platform for healthcare professionals, providing patient file management, biometric data visualization, alert management, teleconsultation, secure messaging, and automated billing. HDS-certified, compatible with Mon Espace Santé, and designed for both cardiac and renal remote monitoring pathways.
• LVAD Monitoring Module Complementary remote monitoring capability for patients implanted with a left ventricular assist device (LVAD). Adds LVAD-specific data capture, follow-up, and billing on top of the Newcard cardiac remote monitoring service.
• Newcard ePRO Electronic patient-reported outcome (ePRO) data collection tool for real-world clinical studies, leveraging Newcard's connected device ecosystem and platform to capture patient-reported data outside the clinic.
• Newcard eCRF Electronic case report form (eCRF) tool for clinical studies, providing structured data collection on top of Newcard's connected device and platform infrastructure for sponsors and CROs.

Quantifiable outcome

• Heart failure hospitalization rate reduced from 44.9% to 11.6% (74.2% relative reduction, p<0.0001) with NNT of 3 over 12 months.
• +6 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core, major and minor.

• Avenir Télématique (ATE)coreTechnology or IntegrationATE (Avenir Télématique) is Newcard's HDS-certified health data hosting provider, located at 24 rue du Gouverneur Général Eboué, Issy-les-Moulineaux (92130). All patient health data is stored in France with no transfer outside the European Union. ATE is listed in Newcard's data processing agreement as a sub-processor.
• La Plateforme Médicale (LPM)majorImplementation/ SI/ Consulting PartnerLPM (La Plateforme Médicale), based at 10 rue Rosenwald, Paris (75015), provides patient training on the use of connected devices and therapeutic support services. Listed as a sub-processor in Newcard's data processing agreement. Services are delivered in France with no data transfer outside the EU.
• SantélysmajorImplementation/ SI/ Consulting PartnerSantélys, based at 351 rue Ambroise Paré, Loos (59120), provides therapeutic support services to Newcard patients. Listed as a sub-processor in Newcard's data processing agreement, operating in France with no international data transfer.
• RESIPcoreTechnology or IntegrationRESIP, based at 84A boulevard Chanzy, Boulogne-sur-Mer (62200), provides the jFSE billing engine integrated into Newcard's platform for SESAM-Vitale electronic claims processing. This integration enables automated billing of remote monitoring acts directly within the Newcard platform, eliminating the need for external billing software. RESIP is listed as a sub-processor in Newcard's data processing agreement.
• EurasantéminorOthersNewcard was incubated within the Eurasanté bio-incubator in Lille. Eurasanté is a health industry cluster that supports innovative companies in the Lille metropolitan area. Newcard remains a member of the Eurasanté pole of excellence.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Implicity: French cardiac remote monitoring platform serving cardiologists with AI-driven arrhythmia detection and alert management. Closest direct competitor to Newcard in the French cardiology tele-monitoring market, targeting overlapping prescriber segments and reimbursement frameworks.
• Satelia: French tele-monitoring company focused on chronic disease management (cardiac, renal, diabetes) reimbursed by Assurance Maladie. Direct competitor sharing the same payer, similar patient populations, and B2B2C prescribers-as-customers model.
• Biosency: French connected health company developing RPM solutions for chronic respiratory and cardiac patients using wearable devices and a clinical platform. Comparable in target conditions, connected device approach, and French/European go-to-market.

Broad incumbents

• Withings: French consumer and clinical connected health company producing connected scales, blood pressure monitors, and a remote patient monitoring suite. Comparable in underlying devices and chronic disease monitoring ambitions, but operates at much larger scale and broader scope than Newcard.
• Philips (Population Health Management / RPM): Global medtech incumbent with extensive remote patient monitoring and chronic disease management offerings, including cardiology. Comparable as a chronic care RPM platform serving hospitals and prescribers, though it operates at vastly greater scale and across multiple specialties.
• Medtronic (Cardiac Diagnostics & Services): Global cardiac device leader with remote monitoring capabilities (e.g., CareLink) for heart failure and arrhythmia patients. Comparable in cardiac chronic disease monitoring and prescriber relationships, but anchored in implanted device telemetry rather than vitals kits.
• Boston Scientific (Cardiac Diagnostics): Global cardiac device and diagnostics company with remote monitoring offerings for heart failure and rhythm management. Comparable as a cardiac monitoring player, though at a much larger scale and focused on device-generated data.
• GE HealthCare (Patient Monitoring): Global patient monitoring and digital health incumbent serving hospitals with continuous vitals monitoring and care management solutions. Comparable in hospital-channel remote monitoring for chronic patients, but operates as a large diversified vendor.

Emerging players

• iRhythm Technologies: US-based cardiac monitoring company (Zio patch and AI ECG platform) focused on ambulatory arrhythmia and heart failure detection. Comparable in cardiac digital health/AI alerting for cardiologists, though US-centric and at higher device classification than Newcard.
• Biofourmis: Global RPM and predictive analytics platform for chronic disease management including heart failure. Comparable in AI-driven alerts, chronic disease focus, and B2B hospital/prescribers model, though more US/Asia-weighted than Newcard.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInfr.linkedin.com/company/newcard.io

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Newcard